Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Hepatitis C

Free Subscription Articles published in Scand J Gastroenterol Retrieve available abstracts of 12 articles: HTML format Text format

Single Articles

November 2018
1. KILENG H, Kjellin M, Akaberi D, Bergfors A, et al
   Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.
   Scand J Gastroenterol. 2018 Nov 5:1-7. doi: 10.1080/00365521.2018.1511824.
   PubMed     Text format     Abstract available
   
   
   July 2018
2. LUND LAURSEN T, Brockner Siggard C, Kazankov K, Damgaard Sandahl T, et al
   Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology.
   Scand J Gastroenterol. 2018 Jul 10:1-8. doi: 10.1080/00365521.2018.1481996.
   PubMed     Text format     Abstract available
   
   
   
3. ZUBKIN ML, Abdurakhmanov DT, Sagalova OI, Bakulin IG, et al
   Persistent mixed cryoglobulinemia after successful antiviral treatment of chronic hepatitis C virus infection: What's the next?
   Scand J Gastroenterol. 2018 Jul 2:1-2. doi: 10.1080/00365521.2018.1477988.
   PubMed     Text format    
   
   
   June 2018
4. MILLBOURN C, Psaros Einberg A, Lindh G, Hokeberg I, et al
   Prevalence and outcome of post-transfusion hepatitis C acquired at different ages and detected in look-back screening.
   Scand J Gastroenterol. 2018 Jun 18:1-6. doi: 10.1080/00365521.2018.1476911.
   PubMed     Text format     Abstract available
   
   
   May 2018
5. CARVALHO JR, Velosa J, Serejo F
   Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens.
   Scand J Gastroenterol. 2018 May 20:1-7. doi: 10.1080/00365521.2018.1473486.
   PubMed     Text format     Abstract available
   
   
   
6. SOLUND C, Hallager S, Pedersen MS, Fahnoe U, et al
   Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation.
   Scand J Gastroenterol. 2018 May 2:1-8. doi: 10.1080/00365521.2018.1467963.
   PubMed     Text format     Abstract available
   
   
   January 2018
7. BARTH C, Neusser S, Biermann J, Wasem J, et al
   Budget impact analysis on the introduction of a guideline based hepatitis B and C screening into a routine check-up in the German primary care setting.
   Scand J Gastroenterol. 2018;53:76-82.
   PubMed     Text format     Abstract available
   
   
   October 2017
8. HANSEN JF, Juul Nielsen M, Nystrom K, Leeming DJ, et al
   PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C.
   Scand J Gastroenterol. 2017 Oct 25:1-5. doi: 10.1080/00365521.2017.1392596.
   PubMed     Text format     Abstract available
   
   
   July 2017
9. 
   Correction to: Castedal et al., IFN-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
   Scand J Gastroenterol. 2017 Jul 13:1. doi: 10.1080/00365521.2017.1354499.
   PubMed     Text format    
   
   
   May 2017
10. MARIA C, Michael S, Susanne C, Catarina S, et al
    INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
    Scand J Gastroenterol. 2017;52:585-588.
    PubMed     Text format     Abstract available
    
    
    October 2016
11. ZHU H, Wu J, Shen X
    Genome-wide association study: new genetic insights into HBV/HCV-related hepatocellular carcinoma genomes.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available
    
    
    July 2016
12. MURUNGA E, Andersson M, Rensburg Cv
    Autoimmune hepatitis: a manifestation of immune reconstitution inflammatory syndrome in HIV infected patients?
    Scand J Gastroenterol. 2016;51:814-8.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: